Astria Therapeutics Inc
ATXS6.834USD
+0.274+4.18%
Horário de mercado （ET）Cotações atrasadas em 15 min
385.69MValor de mercado
PerdaP/L TTM
Mais detalhes de Astria Therapeutics Inc Empresa
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.
Informações da empresa
Código da empresaATXS
Nome da EmpresaAstria Therapeutics Inc
Data de listagemJun 25, 2015
CEODr. Jill C. Milne, Ph.D.
Número de funcionários78
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 25
Endereço22 Boston Wharf Road
CidadeBOSTON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02210
Telefone16173491971
Sitehttps://astriatx.com/
Código da empresaATXS
Data de listagemJun 25, 2015
CEODr. Jill C. Milne, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Mr. Andrew Komjathy
Mr. Andrew Komjathy
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Benjamin Scott Harshbarger
Mr. Benjamin Scott Harshbarger
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Andrea Matthews
Ms. Andrea Matthews
Chief Business Officer
Chief Business Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Perceptive Advisors LLC
11.49%
RA Capital Management, LP
9.05%
Fidelity Management & Research Company LLC
8.52%
Vestal Point Capital, LP
7.41%
Forbion Capital Partners
6.77%
Other
56.77%
Investidores
Investidores
Proporção
Perceptive Advisors LLC
11.49%
RA Capital Management, LP
9.05%
Fidelity Management & Research Company LLC
8.52%
Vestal Point Capital, LP
7.41%
Forbion Capital Partners
6.77%
Other
56.77%
Tipos de investidores
Investidores
Proporção
Investment Advisor
32.69%
Venture Capital
23.81%
Hedge Fund
19.93%
Investment Advisor/Hedge Fund
16.86%
Private Equity
11.49%
Research Firm
1.00%
Individual Investor
0.49%
Pension Fund
0.21%
Bank and Trust
0.19%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
263
60.20M
106.68%
-10.73M
2025Q1
281
59.08M
104.77%
-12.46M
2024Q4
268
59.35M
105.17%
-9.44M
2024Q3
247
57.14M
101.27%
-10.09M
2024Q2
228
56.25M
102.41%
-8.30M
2024Q1
210
58.30M
106.65%
+7.30M
2023Q4
179
37.20M
102.69%
+9.26M
2023Q3
171
23.97M
88.11%
-4.33M
2023Q2
175
25.83M
94.82%
-888.95K
2023Q1
166
24.59M
91.65%
-670.60K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Perceptive Advisors LLC
6.49M
11.49%
--
--
Mar 31, 2025
RA Capital Management, LP
5.11M
9.05%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
4.81M
8.52%
-846.00K
-14.97%
Mar 31, 2025
Vestal Point Capital, LP
4.18M
7.41%
--
--
Mar 31, 2025
Forbion Capital Partners
3.82M
6.77%
+950.00K
+33.07%
Mar 31, 2025
Fairmount Funds Management LLC
3.55M
6.3%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.40M
6.03%
-66.23K
-1.91%
Mar 31, 2025
Millennium Management LLC
2.94M
5.21%
+1.30M
+79.78%
Jun 13, 2025
TCG Crossover Management, LLC
2.76M
4.89%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.64M
4.68%
-29.10K
-1.09%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
ALPS Medical Breakthroughs ETF
0.2%
iShares Micro-Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Ver Mais
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.86%
ALPS Medical Breakthroughs ETF
Proporção0.2%
iShares Micro-Cap ETF
Proporção0.05%
ProShares Ultra Nasdaq Biotechnology
Proporção0.03%
Invesco Nasdaq Biotechnology ETF
Proporção0.03%
iShares Biotechnology ETF
Proporção0.02%
iShares Russell 2000 Value ETF
Proporção0.02%
Avantis US Small Cap Equity ETF
Proporção0.02%
iShares Russell 2000 ETF
Proporção0.01%
ProShares Hedge Replication ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Data
Tipo
Proporção
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
